Edition:
United Kingdom

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

11.65EUR
23 May 2018
Change (% chg)

€0.06 (+0.52%)
Prev Close
€11.59
Open
€11.59
Day's High
€11.69
Day's Low
€11.34
Volume
598,211
Avg. Vol
423,856
52-wk High
€15.80
52-wk Low
€7.28

Chart for

About

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)

Overall

Beta: 0.38
Market Cap(Mil.): €1,457.98
Shares Outstanding(Mil.): 172.95
Dividend: 0.19
Yield (%): 2.25

Financials

  ALM.MC Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.45 -- --
ROI: -3.49 14.84 14.38
ROE: -5.42 16.34 16.07

BRIEF-Almirall Sees 20 Pct EBITDA Growth In 2018

* FY EBITDA 142.2 MILLION EUROS VERSUS 227.6 MILLION EUROS YEAR AGO

23 Feb 2018

BRIEF-Almirall FY Net Result Turns To Loss Of 304 Million Euros

* FY NET LOSS 304.0 MILLION EUROS VERSUS PROFIT OF 75.5 MILLION EUROS YEAR AGO

23 Feb 2018

BRIEF-Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain

* EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN)

22 Dec 2017

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

11 Dec 2017

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​

04 Dec 2017

Earnings vs. Estimates